$261 Million is the total value of Foresite Capital Management III, LLC's 25 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 55.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Sell | Aerie Pharmaceuticals, Inc. | $72,410,000 | +19.7% | 1,596,701 | -0.1% | 27.79% | +5.7% |
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $33,888,000 | +0.1% | 1,629,222 | +0.1% | 13.01% | -11.6% |
| AKAOQ | Sell | Achaogen, Inc. | $31,416,000 | -7.5% | 1,245,187 | -52.3% | 12.06% | -18.3% |
| AIMT | Buy | Aimmune Therapeutics, Inc. | $19,818,000 | +7.2% | 912,001 | +0.9% | 7.61% | -5.3% |
| WVE | WAVE Life Sciences Ltd. | $18,594,000 | +5.2% | 676,128 | 0.0% | 7.14% | -7.1% | |
| EPZM | Buy | Epizyme, Inc. | $11,695,000 | +59.7% | 681,922 | +12.7% | 4.49% | +41.1% |
| BLCM | New | Bellicum Pharmaceuticals, Inc. | $11,328,000 | – | 918,000 | +100.0% | 4.35% | – |
| BPMC | Sell | Blueprint Medicines Corporation | $10,413,000 | +23.7% | 260,400 | -13.2% | 4.00% | +9.3% |
| NSTG | Sell | NanoString Technologies, Inc. | $6,330,000 | -35.2% | 318,586 | -27.3% | 2.43% | -42.8% |
| DERM | New | Dermira, Inc. | $6,011,000 | – | 176,211 | +100.0% | 2.31% | – |
| MNTA | New | Momenta Pharmaceuticals, Inc. | $5,749,000 | – | 430,632 | +100.0% | 2.21% | – |
| PTGX | Protagonist Therapeutics, Inc. | $4,436,000 | -41.7% | 346,281 | 0.0% | 1.70% | -48.5% | |
| LOXO | New | Loxo Oncology, Inc. | $4,208,000 | – | 100,000 | +100.0% | 1.62% | – |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $4,175,000 | -1.3% | 140,000 | -10.1% | 1.60% | -12.8% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $2,800,000 | -23.1% | 100,000 | -44.4% | 1.08% | -32.1% |
| IRTC | Sell | iRhythm Technologies, Inc. | $2,632,000 | -47.2% | 70,010 | -57.9% | 1.01% | -53.4% |
| NTRA | New | Natera, Inc. | $2,534,000 | – | 285,731 | +100.0% | 0.97% | – |
| FGEN | New | Fibrogen, Inc. | $2,169,000 | – | 87,984 | +100.0% | 0.83% | – |
| NTLA | Sell | Intellia Therapeutics, Inc. | $2,114,000 | -77.1% | 150,000 | -78.7% | 0.81% | -79.8% |
| JNCE | New | Jounce Therapeutics, Inc. | $2,014,000 | – | 91,600 | +100.0% | 0.77% | – |
| ZFGN | Sell | Zafgen, Inc. | $1,728,000 | +15.7% | 370,876 | -21.0% | 0.66% | +2.2% |
| OREXQ | Buy | Orexigen Therapeutics, Inc. | $1,309,000 | +196.2% | 380,530 | +49.7% | 0.50% | +161.5% |
| BOLD | Audentes Therapeutics, Inc. | $1,134,000 | -6.7% | 66,553 | 0.0% | 0.44% | -17.6% | |
| IMMU | New | Immunomedics, Inc. | $1,118,000 | – | 172,871 | +100.0% | 0.43% | – |
| XLRN | Acceleron Pharma Inc. | $526,000 | +3.7% | 19,886 | 0.0% | 0.20% | -8.2% | |
| GBT | Exit | Global Blood Therapeutics, Inc. | $0 | – | -63,627 | -100.0% | -0.40% | – |
| AKTX | Exit | Akari Therapeutics, PLCsponsored adr | $0 | – | -197,072 | -100.0% | -0.60% | – |
| EDIT | Exit | Editas Medicine, Inc. | $0 | – | -274,910 | -100.0% | -1.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.